Articles tagged with Tuberculosis
Researchers found that multi-drug tolerant organisms can form within days of infection in zebrafish and grow inside host macrophages, helping to promote the continuation of TB. Inexpensive drugs like verapamil may block tolerance mechanisms, potentially shortening treatment duration.
Researchers used whole genome sequencing to analyze TB bacterial samples from 41 patients. The study found that the outbreak was caused by bursts of transmission, rather than chains of infection.
Researchers at VIB and Ghent University have developed a new tuberculosis vaccine that affords better protection against the disease by triggering an immune reaction in the body. The new vaccine works differently from existing vaccines and acquires its extra protective value by emitting signals that provoke inflammation.
A study by St. Michael's Hospital found that one in five homeless people with tuberculosis die within a year of diagnosis, emphasizing the need for enhanced prevention and treatment strategies.
Scientists at EMBL identified a multi-tasking protein PriA from Mycobacterium tuberculosis that catalyzes reactions on two different molecules. This finding presents new opportunities for developing organism-specific drugs, targeting the pathogen but leaving other beneficial microorganisms untouched.
A recent outbreak of tuberculosis in Nunavut, with a population infection rate 62 times the Canadian average, underscores the need for rebuilding trust in public health. The territory's historical legacy of mistreating patients and lack of consistent screening measures have hindered control efforts.
A new study reveals that standardized medication dosages for children with tuberculosis are too low and may not be effective due to individual variations in response. The researchers used computer simulations to determine how a child's body handles the medication, highlighting the need for personalized treatment plans.
Researchers combined two proteins and a stress response protein to create a new TB vaccine strategy that provided stronger, more long-lasting protection than the current BCG vaccine. The study found that this multistage vaccine controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively.
A simple, standardized TB screening rule has been developed for resource-constrained settings to identify people living with HIV who need further investigation for TB disease. The absence of common symptoms such as cough, fever, and night sweats can be used to identify individuals with a low probability of having TB disease.
Researchers studied TB detection methods in western Kenya and found that passive case finding is inadequate due to the high prevalence of HIV. Intensive methods like sputum culture are needed to diagnose TB earlier and more accurately, especially among men and those with prior TB treatment.
A new study published in CMAJ found that people over 65 undergoing latent tuberculosis infection therapy are at a higher risk of severe adverse reactions requiring hospitalization. The study provides age-stratified estimates of the risk of these events, accounting for comorbidities and similar health events in the general population.
A new study found that supplementing antibiotics with high-dose vitamin D can significantly reduce the time needed for TB bacteria to clear from sputum culture by almost a week in patients with specific genetic profiles. The treatment improved response in those with the tt genotype of the TaqI vitamin D receptor polymorphism.
New research shows vitamin D can speed up antibiotic treatment of tuberculosis (TB), clearing bacteria from the lungs in just 5 weeks for certain patients. Vitamin D deficiency is a common problem among TB patients, and those with a specific genetic type of vitamin D receptor responded better to supplementation.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
The Lancet's Editorial in 1911 highlighted issues such as tuberculosis, occupational health, and homoeopathy, which remain relevant today. The journal has made significant advances in medicine since then, including modernizing medical education.
A systematic review found that prison TB spread significantly increases the incidence of TB in the general population. The average incidence of TB in prisons was 23 times higher than in the general population.
The UK is experiencing a resurgence of tuberculosis, with London accounting for over 40% of all TB cases. The disease is concentrated in high-risk groups, including migrants, homeless people, and prisoners. Experts call for urgent recommendations to be implemented to control the spread.
Researchers found that Mycobacterium chelonae, a common environmental bacterium, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine. The study suggests that immune cells exposed to this bacterium may dampen vaccine efficacy. This discovery could lead to new, more effective vaccines against tuberculosis.
Two iron compounds have been synthesized to inhibit the growth of Mycobacterium tuberculosis in vitro. The compounds showed low toxicity in mammalian cells, making them promising candidates for treating tuberculosis and serving as hospital disinfectants.
A combination of increased domestic funding and foreign loans led to a dramatic increase in tuberculosis case finding in China. The study highlights the importance of evaluating the links between financing for health and TB control.
Scientists identified a key enzyme in Mycobacterium tuberculosis that can be targeted for new TB treatments. Three compounds were found to inhibit the enzyme effectively, killing bacterial cells.
Researchers have developed an inhalable dry powder antibiotic targeting TB, potentially reducing treatment time from 6-12 months to under a year. The novel treatment aims to distribute antibiotics directly to lung lesions, increasing targeted doses and minimizing side effects.
The Aeras Global TB Vaccine Foundation has received an additional €11.7 million grant from the Netherlands Ministry of Foreign Affairs to develop new vaccines against tuberculosis.
The microscopic observation drug susceptibility (MODS) test has been endorsed by WHO for use in resource-poor settings. The test delivers positive culture and drug resistance results within two weeks for less than $3 per test, improving TB diagnosis and treatment.
Weill Cornell Medical College has received $200,000 in new funding from the Gates Foundation for tuberculosis research. The grants will support projects led by Dr. Carl Nathan and Dr. Kyu Rhee, aiming to understand the genetic mechanism of TB emergence from latency and develop new therapies.
Researchers linked hundreds of approved drugs to M. tuberculosis proteins, identifying new anti-tuberculosis targets and repurposing potential. The study provides a promising computational strategy for novel drug discovery.
Researchers found that people with periodontal disease are at high risk for cardiovascular disease and that invasive dental procedures may raise this risk. However, studies have not consistently shown a link between these procedures and cardiovascular events. Meanwhile, peer support programs improved diabetes management in patients, su...
Scientists discovered a key difference in how TB bacteria and human cells deliver unwanted proteins to their respective recycling factories. This critical difference may help design drugs to disable the bacterial system while leaving normal human protein recycling centers intact.
A new tool has been developed to tackle tuberculosis by integrating genomic and metabolic data, enabling cell-scale simulations and biological strain design. The probabilistic regulation of metabolism (PROM) algorithm accurately predicts knockout phenotypes 95% of the time, paving the way for targeted research during dormancy.
The Aeras Global TB Vaccine Foundation has received a $362,102 grant from the US FDA to develop new biological and immunological biomarkers for TB vaccine development. The project aims to evaluate four mycobacterial growth inhibition assays and identify T-cell immune responses associated with protective vaccines.
A mobile van approach to hunt down active cases of tuberculosis significantly outperformed door-to-door visits, detecting 255 smear-positive patients vs. 137 through door-to-door visits. This intervention led to a 43% decline in undiagnosed culture-positive TB in the community.
Kathleen Alexander has discovered a novel tuberculosis species, M. mungi, in banded mongooses, which behaves differently from other TB infections, killing infected animals within two to three months. The pathogen's source and host range are areas of ongoing research.
A computer model shows that the US is susceptible to MDR-TB epidemics when TB prevalence falls and case detection improves, even with high treatment compliance. This is attributed to the increased risk of drug-resistant TB spreading in populations with low drug-susceptible TB rates.
Dr. Jerrold J. Ellner leads an international research team to identify biological markers for tuberculosis (TB) and develop novel treatments and vaccines. The five-year grant aims to prevent TB, which kills nearly two million people annually.
Researchers at NPL and Orla Protein Technologies are developing improved TB detection methods to enhance sensitivity, specificity, cost and speed. The project aims to create systems that advance current methods, helping improve healthcare in resource-limiting settings.
A new TB vaccine candidate called AERAS-422 is undergoing clinical trials to evaluate its safety and immunogenicity. The vaccine aims to interrupt TB at all stages of infection, including initial infection, latency, and reactivation.
The Phase II study will establish the optimal dosing regimen and then be tested in Kenya, Mozambique, South Africa, and Uganda. The TB vaccine candidate has been shown to have an acceptable safety profile in early-stage clinical trials.
Recent research suggests that some TB vaccines under study may not be effective in older people, as the molecule responsible for immune response activation remains relatively inactive. The study's findings highlight the need for a new approach to vaccine development to ensure protection against tuberculosis for the elderly.
A computer model found a network of genes that can trigger TB's dormant state, switching it from fast-growing to slow-growing. The study reveals potential for a persistence switch that could explain why TB is so widespread and deadly.
A team from Case Western Reserve University has identified a novel dual recognition mechanism in Mycobacterium tuberculosis that may contribute to immune evasion. The discovery could aid in the design of new vaccines and antibiotics to combat the disease.
Researchers discovered that mycobacteria block phagosome maturation with acyltrehalose-containing glycolipids, surviving and thriving inside host macrophages. This study sheds light on the mechanism of intracellular parasitism and identifies potential new drug targets for TB treatment.
A new molecular test has been shown to diagnose tuberculosis (TB) and detect drug-resistant bacteria with high sensitivity and specificity. The Xpert MTB/RIF TB test successfully identified 98% of confirmed TB cases and patients with rifampin-resistant bacteria in under two hours.
Scientists at Nationwide Children's Hospital have discovered a distinct blood transcriptional signature associated with active TB, which may help identify patients at risk of developing the disease. The study found that this signature was present in 10-20% of latent TB patients and correlated with disease extent in active TB patients.
The Open Source Drug Discovery (OSDD) Consortium is a worldwide scientific community working together to discover and develop new drugs. Key findings include the development of a comprehensive map of Mycobacterium tuberculosis genome, paving the way for a potential new drug for tuberculosis.
Researchers will study immune cells to identify biomarkers associated with TB infection and disease reactivation. The joint laboratory aims to develop early diagnosis and effective treatment for the highly contagious disease, affecting millions worldwide.
Researchers identified a genetic variant on chromosome 18 associated with increased TB susceptibility in African populations. The study demonstrates the feasibility of genome-wide association studies in Africa, which have been successful in European populations but faced challenges due to high genetic diversity.
Rice University's compact fluorescence microscope, developed by Andrew Miller, has been shown to accurately diagnose tuberculosis in a trial with 98.4% accuracy. The portable device, costing $240, is comparable to expensive lab equipment and has the potential to improve early detection and treatment of TB in developing countries.
Leading respiratory specialists call for a new approach to TB screening for newly arrived immigrants from high-risk countries. They argue that the current system is fundamentally flawed and fails to address the growing number of TB cases in the UK. The authors propose screening new arrivals in community services, rather than relying on...
Researchers developed an alphavirus vector to overcome neutralizing antibodies and induce immune responses in humans with advanced cancer. Genetic mutations determined breast cancer subtype by influencing Rb gene expression.
Researchers found that TB bacteria tip the balance between cell death types, affecting immune response. Drugs targeting eicosanoid production may offer new treatment options for TB.
A five-year, $4 million NIH grant will support a prospective study on antiretroviral therapy for people co-infected with MDR-TB and HIV in South Africa. The study aims to gather evidence for clinical practice and public health policy worldwide.
A new diagnostic technique called microscopic-observation drug-susceptibility (MODS) has been shown to be significantly more sensitive and faster than conventional culture tests, diagnosing 70% more cases of pulmonary TB among children under 12. This is the best available test for confirming paediatric pulmonary tuberculosis in resourc...
A clinical trial in Cambodia found that starting anti-HIV therapy two weeks after beginning TB treatment boosts survival rates for HIV-infected adults with weak immune systems. This approach, compared to waiting eight weeks, shows a significant difference in mortality rates among participants.
A postmortem study in South Africa reveals high TB prevalence and late diagnosis among HIV-positive patients. The study suggests that early tuberculosis screening and treatment can reduce the global death toll from TB.
Researchers will investigate person-to-person transmission of XDR-TB using advanced epidemiologic techniques and social network analysis. The findings could alter public health approaches for controlling the XDR-TB epidemic in sub-Saharan Africa.
Scientists have discovered that CCL5 plays a protective role in warding off tuberculosis by attracting immune cells to infection sites. The protein may lead to new therapies that help the immune system resist TB, providing hope for treating this global disease.
Scientists found that M. tuberculosis antigens remain unchanged and homogenous, unlike many viruses and parasites, allowing the bacteria to be transmitted from person to person.
New scientific advances offer significant promise for reducing the spread of HIV/AIDS and tuberculosis, including novel TB drugs, rapid diagnostic tests and bold prevention approaches like PrEP. Experts call for policymakers to capitalize on these advances to save millions of lives from these deadly epidemics.
The TB Alliance has made significant progress in developing new TB drugs, with three co-developed by the organization and its partners, and two others currently being tested through the Critical Path to TB Regimens (CPTR) initiative.
The commentary emphasizes the need for improved TB diagnosis and treatment access, surveillance, and investment in new drugs, diagnostics, and a vaccine. Migrants face significant health disparities due to inadequate treatment and poor public health infrastructure.